GW was founded in 1998. GW Pharmaceuticals has "high" hopes that its products will help relieve the pain and muscle stiffness that have resulted from cancer, multiple sclerosis, and surgery. The company develops prescription medicinal drugs derived from an hybrid form of cannabis that doesn't cause a psychotropic high. GW's lead drug candidate is Sativex, a whole-plant cannabis extract delivered by an oral spray. Sativex has been approved in Canada for the treatment of pain caused by multiple sclerosis. The company has agreed to let Bayer market the drug in the UK and Canada.

IS Pharma, formerly known as Maelor, is a UK-based drug and medical device company focused on products for the hospital market; it sells directly in the UK and uses distributors elsewhere. Among its products are Volpex, Haemopressin, and ISOplex, all critical care products used in surgery; Mysoline, an oral treatment for epilepsy; and Cryogesic and Aloxi, two cancer drugs. Maelor outlicenses some products outside its core focus areas to other firms, including its OptiFlo catheter, which is distributed by C.R. Bard. Previously limited primarily to the UK market, the firm bought Swiss drug firm Specialty European Pharma International in 2008, giving it a wider presence in Europe and in North America.

Dyax Corp. was founded in 1989 and is headquartered in Cambridge, Massachusetts. Dyax Corp. (Dyax) is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel biotherapeutics for unmet medical needs, with an emphasis on inflammatory and oncology indications. The Company uses the drug discovery technology, known as phage display, to identify antibody, small protein and peptide compounds for clinical development. The Company’s product DX-88 (ecallantide), is in late stage clinical trial development in two separate indications. In addition to DX-88, the phage display technology has allowed Dyax to develop a substantial pipeline of drug candidates. In June 2008, the Company completed a second phase three study, known as EDEMA4.

Afexa Life Sciences (formerly CV Technologies) bets that mother nature is always right, but it offers a guarantee just in case. The company uses its ChemBioPrint technology to identify and measure the contents and biological activity of natural health products to ensure batches of herbs and natural compounds are safe and consistent. The company originated as a spin-off from the Faculty of Medicine at the University of Alberta in 1992, and now focuses on the development and manufacturing of natural health products for disease prevention and health maintenance for everyday consumers, especially athletes. COLD-fX is Afexa's lead product and works to strengthen the immune system to prevent colds and the flu.

Labcyte Inc. company sells automated dispensing systems, plate assemblers, microplates, and labware supplies. Labcyte's products are built around a liquid management technology it calls Acoustic Droplet Ejection (ADE) which uses sound energy to move miniscule bits of liquid without any physical contact during transfer. ADE is useful where cross-contamination would compromise quality or data and it reduces the waste created by disposable liquid handling supplies. Labcyte's customers include pharmaceutical and biomedical research labs. The company has expanded distribution of its products into Europe and Asia.

Mymetics Corporation is a biotechnology research and development company focused on fundamental and applied research in the area of human biology and medicine. Mymetics's primary objective is to develop vaccines and therapies to prevent and treat the effects of certain retroviruses and other infectious diseases, including the human immunodeficiency virus (HIV), the virus that leads to acquired immunodeficiency syndrome (AIDS). Mymetics has also acquired from a scientific partner an advanced malaria vaccine project, which is in phase II clinical trial. Additional applications of Mymetics's research include potential treatments and/or vaccines for malaria, human oncoviral leukemias, multiple sclerosis and organ transplantation. In April 2009, the Company completed the acquisition of Bestewil Holding B.V. and its subsidiary, Virosome Biologicals B.V., from Norwood Immunology Limited.

MorphoSys is a biotechnology firm with a human touch. Using its proprietary HuCAL catalog of fully human antibodies, the company is helping the world's largest drug firms develop human antibody therapies for a wide range of diseases. It helps its pharmaceutical clients in a number of ways: one, by installing its HuCAL library and related technology at customer sites in return for licensing fees; and second, by working in partnership with drug firms to develop potential antibody therapies. Its client list is a Who's Who of Big Pharma and includes Novartis, Pfizer, Roche, and Merck. MorphoSys also makes human antibodies (under the brand name AbD-Serotec) and sells them to researchers.

The Wellcome Trust Sanger Institute (Sanger Institute) is a leading research center dedicated to analyzing and understanding genomics. Best known for its work on the Human Genome Project (the institute is responsible for sequencing one-third of the human genome), the Sanger Institute is applying genomics to the study of organisms that cause diseases such as malaria, typhoid, and tuberculosis. The institute was founded in 1993 by the Wellcome Trust and the Medical Research Council, and has been funded by a $430 million grant from the Wellcome Trust since 2001.

MPI Research was founded in 1962. MPI Research helps drug developers answer a crucial question: Is it safe? The contract research organization (CRO) specializes in providing pre-clinical research services to pharmaceutical, medical device, chemical, and agricultural development companies, as well as regulatory and other government agencies. Its toxicology testing services investigate and determine the safety and dosage levels of substances being considered for use in drugs, pesticides, petrochemicals, and food additives. MPI Research also offers contract bioanalytical and pharmacology services.

Icagen, Inc. company was founded in 1992 and is based in Durham, North Carolina. Icagen, Inc. (Icagen) is a biopharmaceutical company focused on the discovery, development and commercialization of orally-administered small molecule drugs that modulate ion channel targets. The Company’s programs include ICA-105665 for epilepsy and neuropathic pain, for which the Company is conducting a Phase I multiple ascending dose study in healthy volunteers and epilepsy patients and Senicapoc, previously referred to as ICA-17043, for asthma, for which the Company is conducting two Phase II proof-of-concept clinical trials.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.